Molecularbiological background of inflammatory bowel disease;Gyulladásos bélbetegségek molekuláris biológiai háttere

Orvosi Hetilap

Volumn 147, Issue 30, 2006, Pages 1395-1403

  Miheller, Pál ^a,b   Muzes, Györgyi ^a   Galamb, Orsolya ^a   Molnár, Béla ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Kutató Csoport ^*  (Hungary)

Author keywords

Biological therapy; Citokines; Genetik; Inflammatory bowel disease; Pathogenesis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; LYMPHOTOXIN 3 ALPHA; ORGANIC CATION TRANSPORTER; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL RESPONSE MODIFIER; CARD15 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; SIGNAL PEPTIDE; SLC22A4 PROTEIN, HUMAN; SLC22A5 PROTEIN, HUMAN; TLR5 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ARTICLE; CELL FUNCTION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENTERITIS; GENE FUNCTION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOREGULATION; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; MOLECULAR BIOLOGY; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SPINAL GANGLION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOCYTE ACTIVATION; METABOLISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL RESPONSE MODIFIERS; CROHN DISEASE; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; INTESTINAL MUCOSA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; NOD2 SIGNALING ADAPTOR PROTEIN; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 5; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749320417     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Alexopoulou, L., Pasparakis, M.: Complementation of lymphotoxin knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function. J. Exp. Med., 1998, 188, 745-754.
2. Binion, D. G., Kugathasan, S., Dwinell, M. B.: Molecular stratification of Crohn's disease by kemokine receptors: fractalkine receptor polymorphisms define a fibrostenosing ileal subgroup. Am. J. Gastroenterol., 2006, 101, 107-109.
3. BioPortfolio. IDEC (NASDAQ:IDPH) has halted clinical trials of its therapeutic monoclonal antibody IDEC-131 www.bioportfolio.com/news/btech 0611021.htm
4. Cantor M. J., Nickerson, P., Bernstein, C. és mtsai: The role of citokine gene polymorphism in determining disease suspectibility and phenotype in inflammatory bowel disease. Am. J. Gastroenterol., 2005, 100, 1134-1142.
5. Cher, D. J., Mossmann, T. R.: Two types of murine helper T cell clone. U. Delayed-type hypersensitivity is mediated by Th1 clones. J. Immunol., 1987, 138, 3688-3694.
6. Chowdhury, A., Fukuda, R.: Growth factor mRNA expression in normal cololrectal mucosa and in uninvolved mucosa from ulcertative colitis patients. J. Gastroenterol., 1996, 31, 353-360.
7. Clark, E., Hoare, C., Tanianis-Hughes, J. és mtsai: Interferon gamma induces translocation of commersal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology, 2005, 128, 1258-67.
8. Farrell, R. J., Murphy, A., Long, A. és mtsai: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who failed medical therapy. Gastroenterology, 2000, 118, 279-288.
9. Fries, W., Renda, M. C., Lo Presti M. A. és mtsai: Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am. J. Gastroent., 2005, 100, 2730-2736.
10. Fuss, I. J., Neurath, M., Boirivant, M. és mtsai: Disparate CD4+ lamina propria (LP) lymphokine secterion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased scretion of IL-5. J. Immunol., 1996, 157, 1261-1270.
11. Gewirtz, A., Vijay-Kumar, M., Brandt, S. R. és mtsai: Dominant-negatíve TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290, G1157-1163.
12. Gewirtz, A. T., Navas, T. A., Lyons, S. és mtsai: Cutting edge: bacterial flagellin activates basloaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol., 2001, 16, 1882-1885.
13. Giladi, E., Raz, E.: Transforming growth factor-β gene therapy ameliorates experimental colitis in rats. Eur. J. Gastroenterol. Hepatol., 1995, 7, 341-347.
14. Glas, J., Torok, H. P., Tonenchi, L. és mtsai: Association of polymorphisms in interleukin-18 gene in patients with Crohn's disease depending on the CARD15/NOD2 genotype. Inflamm. Bowel. Dis., 2005, 11, 1031-1037.
15. Haas, S. L., Andreas Koch, W., Schreiber, S. és mtsai: 137 (G/ C) IL-18 polymorphism in patients with inflammatory bowel disease. Scand. J. Gastroenterol., 2005, 40, 1438-1443.
16. Hacker, U. T., Gomolka, M.: Lack of association between interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut, 1997, 40, 623-627.
17. Hilsden, R. J., Meddings, J. B., Sutherlan, L. R. : Intestinal permeability changes in response to acetylsalicilic acid in relatives of patients with Crohn's disease. Gastroenterology, 1996, 110, 1395-1403.
18. Hollander, D., Vadheim, C. M., Brettholz, E. és mtsai: Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med., 1986, 105, 883-885.
19. Hugot, J. P., Chamaillard, M., Zoulai, H.: Association of NOD2 leucin-reach repeat variants with suspectibility to Crohn's disease. Nature, 2001, 411, 599-603.
20. Hyun, J. G., Lee, G., Brown, J. B. és mtsai: Anti-interferon-inducible kemokine, CXCL10, reduces colitis by imparing T helper-1 induction and recruitment in mice. Inflamm. Bowel Disease, 2005, 11, 799-805.
21. Kirkegaard, T, Hansen, A., Bruun, E. és mtsai: Expression and localisaton of matrix metalloproteinases and their natural inhibitorsin fistulae of patients with Crohn's disease. Gut, 2004, 53, 701-709.
22. Klein, W, Tromm, A., Flowaczny, C. és mtsai: A potymorphysm of the bacterial/permeability increasing protein (BPI) gene is associated with Crohn's disease. J. Clin. Gastroenterol., 2005, 39, 282-283.
23. Kojima, K., Musch, M. W., Ropeleski, M. J. és mtsai: Escherichia coli LPS induces heat shock protein 25 in intestinal epithelial cells trought MAP kinases activation. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286, G645-652.
24. Kontoyannis, D., Pasparakis, M., Pizzaro, T. T. és mtsai: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF Au-rich elements: implications for joint and gut-associated immunopathogenesis. Immunity, 1999, 10, 387-398.
25. Kuhn, R., Lohler, J., Rennick, D. és mtsai: Interleukin-10 deficient mice develop chronic enterocolitis. Cell, 1993, 75, 263-274.
26. Lakatos, P. L., Lakatos, L., Szalay, F. és mtsai: Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J. Gastroent., 2005, 11, 1489-1495.
27. Langmann, T, Moehle, C., Mauerer, R. és mtsai: Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology, 2004, 127, 26-40.
28. Lawrence, I., Fiocchi, C., Chakravati, S.: Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel suspoectibility candidate genes. Human Mol. Genetics, 2001, 10, 44-456.
29. Liu, Y., Merlin, D., Burst, S. L. és mtsai: The role of CD47 in neutrophyl transmigration, increased rfate of migration correlates with increased cell surface esxpression of CD47. J. Biol. Chem., 2001, 276, 40156-40166.
30. Lombardi, M. L., Pirozzi, G., Luongo, V. és mtsai: Crohn's disease: suspectibility and disease heterogenity revealed by HLA genotyping. Hum. Immunol., 2001, 62, 701-704.
31. Madsen, K., Cornish, A., Soper, P. és mtsai: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology, 2001, 121, 580-591.
32. Mannon, P. J., Fuss, I. J., Mayer, L. é mtsai: Anti-IL-12 Crohn's Disease Study Group: Anti-interleukin 12 antibody for active Crohn's disease. N. Engl. J. Med., 2004, 35, 2069-2079.
33. McCormic, B. A., Hofman, P. M., Kim, J. és mtsai: Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signaling to subepithelial neutrophyls. J. Cell. Biol., 1993, 123, 895-907.
34. Meijssen, M. A., Brandwein, S. L.: Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2 deficient mice. Am. J. Physiol., 1998, 274, 472-479.
35. Merlin, D., Si-Tahar, M., Sitaraman, S. V.: Clonic epithelial hPepT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class I molecules. Gastroenterology, 2001, 120, 1666-1679.
36. Mosmann, T. R., Sad, S., Krishnan, L. és mtsai: Differentation of subsets of CD4+ and CD8+ T cells. Ciba Found. Symp. 1995, 195, 42-50.
37. Negoro, K., Kinouchi, Y., Hiwatashi, N. és mtsai: Crohn's disease is associated with novel polymorphism in the 5′ flanking region of the tumor necrosis factor gene. Gastroenterology, 1999, 117, 1062-1068.
38. O'Neil, L. A. J.: How NOD-ing off leads to Crohn's disease. Nat. Immunol., 2004, 5, 776-778.
39. Ohtani, H., Kagaya, H.: Immunohistochemical localisation of transforming growth factor-β receptors I and H in inflammatory bowel disease. J. Gastroenterol., 1995, 30, 76-77.
40. Orholm, M., Munkholm, P., Langholz, E. és mtsai: Familial occurence of inflammatory bowel disease. N. Engl. J. Med., 1991, 324, 84-88.
41. Panja, A., Goldberg, S., Eckmann, L. és mtsai: The regulation and functional consequence of proinflammatory citokin binding on human intestinal epithelial cells. J. Immunol., 1998, 161, 3675-3684.
42. Parrelo, T., Monteleone, G., Cucchiara, S. és mtsai: Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J. Immunol., 2000, 165, 7234-7239.
43. Raddatz, D., Bockemuhl, M., Ramadori, G.: Quantitative measurement of citokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Fur. J. Gastroenterol. Hepatol., 2005, 17, 547-555.
44. Rector, A., Vermiere, S., Thoelen, I. és mtsai: Analysis of the CC kemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum. Genet., 2001, 108, 190-193.
45. Roussomoustakaki, M., Satsangi, J., Welsh, K. és mtsai: Genetic markers may predict disease behaviour in patients with ulcerative colitis. Gatsroenterology, 1997, 112, 1845-1853.
46. Rutgeerts, P., Reinisch, W., Colombel, J. F.: Preliminary results of a phase I/II study of Huzaf, an anti-IFN-monoclonal antibody, in patients with moderate to severe active Crohn's disease (absztrakt). Gastreonterology, 2002, 122, A61.
47. Satsangi, J., Parkes, M., Louis, E. és mtsai: Two stage genome-wide search in inflammatory bowel disease provides evidence for suspectibility loci chromosomes 3, 7 and 12. Nat. Genet, 1996, 14, 199-202.
48. Satsangi, J., Welsh, K. I., Bunce, M. és mtsai: Contribution of genes of the major histocompatibility complex to suspectibility and disease phenotype in inflammatory bowel disease. Lancet. 1996, 347, 1212-1217.
49. Scheerens, H., Hessel, E., de Waal-Malefyt, R. és mtsai: Characterisation of kemokines and kemokine receptor sin two murine models of inflammatory bowel disease: IL10 -/- mice and Rag-2 -/- mice reconstituted with CD4+CD45RBright T cells. Eur. J. Inummol., 2001, 31, 1465-1474.
50. Schreiber, S., Heinig T., Thiele, H. G. és mtsa: Immunregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology, 1995, 108, 1434-1444.
51. Stallmasc, A., Marth, T., Adrian, N. és mtsai: Increased expression of interleukin-12 receptor beta(2) on lamina propria mononuclear cells of patients with active Crohn's disease. Int. J. Colorectal. Dis., 2002, 17, 303-310.
52. Suenaert, P., Bulteel, V., Vermeire, S. és mtsai: Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor-necrosis factor dependent. Inflamm. Bowel Dis., 2005, 11, 667-673.
53. Takagawa, T, Tamura, K., Yakeda, N. és mtsai: Association between IL-18 gene promoter polymorphism and inflammatory bowel disease in Japanese population. Inflamm. Bowel Dis., 2005, 11, 1038-1043.
54. Thompson, N. P., Drischoll, R., Pounder, R. E. és mtsa: Genetics versus enviroment in inflammatory bowel disease: results of a British twin study. Br. Med. J., 1993, 306, 20-24.
55. Willemsen, L. E., Hoetjes, J. P., van Deventer, S. J. és mtsa: Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition. Clin. Expl. Immunol., 2005, 142, 275-284.